Clinical Outcome in Patients With Spinal Dural Arteriovenous Fistulas (COPSDAVF)

Sponsor
Hongqi Zhang, MD (Other)
Overall Status
Recruiting
CT.gov ID
NCT03192800
Collaborator
Beijing Haidian Hospital (Other)
300
1
145
2.1

Study Details

Study Description

Brief Summary

Spinal dural arteriovenous fistulas (SDAVFs) are the most common vascular disorder of the spine and account for approximately 70% of spinal vascular malformation.They are a rare pathology with an excepted incidence of only 5-10 new cases per million inhabitants per year. Most fistulas are found in the thoracolumbar region and > 80% of all SDAVFs are located between T6 and L2, whereas the cranio-cervical, cervical and sacral fistulas are more rare. SDAVFs have an overwhelmingly male predominance (80%), with an age presentation in the fifth or sixth dacede. It is presumed that SDAVFs are acquired diseases. A typical SDAVF is located inside the dural mater close to nerve root. It is fed by a radiculomeningeal artery and enters a radicular vein that merges in the perimedullary plexus. The presence of a shunt leads to a reversal of blood flow to the spinal cord venous system, which then induces venous hypertensive myelopathy.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The initial symptoms of venous congestion include gait disturbances, sensory symptoms (hyperesthesia and paresthesia), and sphincter dysfunction. These neurological symptoms are unspecific, so SDAVFs often go clinically underdiagnosed or misdiagnosed. But SDAVFs typically demonstrated a characteristic imaging appearance on spinal MRI including multilevel centromedullary cord T2 hyperintensity, enlarged intradural vessels along the dorsal and ventral aspect of the cord. If an SDAVF is suspected, conventional spinal angiography is required to confirm the diagnosis and determine the location of the fistula. Flowing diagnosis, expedient treatment is required, both microsurgery and endovascular embolization are safe and can achieve complete occlusion, the progression of the neurological deficits can be stopped in most instances.

    However, it is difficult to predict whose symptoms will improve and whose will stabilize or deteriorate. Due to the low incidence of the SDAVFs, nearly all studies which have been published about the clinical outcome and prognostic factors of SDAVFs are relatively limited and most of them are retrospective. In these studies, the preoperative severity of disability, age, gender, location of fistula and duration of symptoms have been analyzed as prognostic factors, therefore it remains unclear which are the most reliable predictor of clinical outcome. Moreover, the conclusions may be biased by long span of follow-up period or few clinical cases. Besides, the fitulas at the craniocervical junction often present with hemorrhage, while those below conus constitute 3 types of lesions. So the invsetigator conduct this prospective cohort study to clarify the 1-year outcome of patients with cervical and thoracolumbar SDAVFs and to determine the main prognostic factors.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Clinical Outcome in Patients With Spinal Dural Arteriovenous Fistulas
    Actual Study Start Date :
    Mar 1, 2013
    Anticipated Primary Completion Date :
    Mar 31, 2023
    Anticipated Study Completion Date :
    Mar 31, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Change of the spinal cord function [1 day before operation and 3 months, 6 months, 12 months postoperation]

      Modified Aminoff & Logue's Scale for evaluating the spinal cord function

    Secondary Outcome Measures

    1. Modified Denis Pain and Numbness Scale (mDPNS) [1 day before operation and 3 months, 6 months, 12 months postoperation]

      mDPNS for evaluating the sensory function of patients with SDAVFs before and after operations

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patient diagnosed with spinal dural arteriovenous fiatulas

    • the fiatula locate between C2 and L5

    • patient not received surgical or interventional treatment before

    • patient with normal cardiac, renal and hepatic function

    • patient capable of understanding the content of the patient information / Informed Consent Form

    • patient willing and able to participate in the registry

    Exclusion Criteria:
    • patient received surgical treatment or interventional treatment before

    • patient is pregnant patient allergic to iodine

    • patient unable to complete follow-up

    • patient with cerebral lesions patient with other spinal lesions

    • patient with cardiac, renal or hepatic dysfunction

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Neurosurgery Department of Xuanwu hospital, Capital Medical University Beijing Beijing China 100053

    Sponsors and Collaborators

    • Hongqi Zhang, MD
    • Beijing Haidian Hospital

    Investigators

    • Study Director: Zhang Hongqi, MD.PHD., Xuanwu Hospital, Beijing

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hongqi Zhang, MD, Director, Xuanwu Hospital, Beijing
    ClinicalTrials.gov Identifier:
    NCT03192800
    Other Study ID Numbers:
    • COPSDAVF
    First Posted:
    Jun 20, 2017
    Last Update Posted:
    Apr 22, 2021
    Last Verified:
    Apr 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hongqi Zhang, MD, Director, Xuanwu Hospital, Beijing
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 22, 2021